Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 62.7% in February

Lonza Group Ag (OTCMKTS:LZAGY) was the target of a large decrease in short interest in February. As of February 13th, there was short interest totaling 8,172 shares, a decrease of 62.7% from the January 29th total of 21,908 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 428,761 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 428,761 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Zacks Research lowered shares of Lonza Group from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 4th. Royal Bank Of Canada raised shares of Lonza Group from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Lonza Group Stock Up 0.7%

Lonza Group stock traded up $0.51 during mid-day trading on Friday, hitting $69.33. 69,462 shares of the company’s stock were exchanged, compared to its average volume of 152,929. The company’s 50 day simple moving average is $68.50 and its 200-day simple moving average is $68.47. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.24. Lonza Group has a fifty-two week low of $55.57 and a fifty-two week high of $73.85.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.